Lyell Immunopharma Inc【LYEL】株式ニュース

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

More than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97%No...

Form 4 - Statement of changes in beneficial ownership of securities

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with...

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

SOUTH SAN FRANCISCO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a...

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a...

Lyell Immunopharma Announces Participation in May Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a...

jondoeuk 1年前

It will be interesting to see GILD's KITE-753 clinical data. The only difference between it (and KITE-363) is a reduced production time.

However, based on preclinical data, KITE-753 exhibited higher expression of both CARs and increased proportion of CCR7+/CD45RA+ T-cells* compared to the KITE-363 benchmark.

Also, KITE-753 exhibited enhanced cytokine production, enhanced proliferation, increased peripheral peak expansion, and superior antitumour efficacy compared to the KITE-363 benchmark.

* CCR7+/CD45RA+CD4+ of ~60% vs ~5%, and CCR7+/CD45RA+CD8+ of ~80% vs ~15%.

High circulating CCR7+ populations positively correlate with antitumour response https://www.nature.com/articles/s41591-020-1061-7

👍 1

jondoeuk 1年前

An update https://www.oncologypipeline.com/apexonco/lyell-takes-jj-and-gilead

👍️0

jondoeuk 1年前

An update on prizlon-cel

👍️0

jondoeuk 1年前

An update on CRGX https://www.fiercebiotech.com/biotech/cargo-jettisons-remaining-assets-and-90-workforce-it-looks-reverse-merger

👍️0

glenn1919 1年前

LYEL..................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783

👍️0

glens0 1年前

https://ih.advfn.com/stock-market/NASDAQ/lyell-immunopharma-LYEL/stock-news/95521325/form-4-statement-of-changes-in-beneficial-owners

👍️0

georgie18 1年前

Yup...LYEL...🥳...Moving up nicely...

LYEL...7008...Off the .56 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 32376

Friday, February 21, 2025 9:40:49 AM

Post#
32428
of 32525
LYEL...6868...🥳...Trying for Double Top Breakout here...Off the .56 Alert...

georgie18

Member Level
Re: georgie18 post# 674836

Thursday, February 20, 2025 2:04:23 PM

Post#
674950
of 675048
LYEL...66...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 32041

Wednesday, February 19, 2025 3:48:52 PM

Post#
32270
of 32375
LYEL...6145...Bullish Engulfing Reversal Candle...🥳

LYEL...639...🥳...Looking for $1 plus here...

georgie18

Member Level
Re: None

Thursday, February 13, 2025 4:20:43 PM

Post#
32007
of 32040
LYEL...56...🥳... https://schrts.co/XneECpDw...https://finance.yahoo.com/news/lyell-immunopharma-lyel-upgraded-strong-170012527.html

This is a Rigatoni Play ...one of the best Traders I have had the pleasure of knowing for many years...

👍️0

georgie18 1年前

LYEL...6868...🥳...Trying for Double Top Breakout here...Off the .56 Alert...

georgie18

Member Level
Re: georgie18 post# 674836

Thursday, February 20, 2025 2:04:23 PM

Post#
674950
of 675048
LYEL...66...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 32041

Wednesday, February 19, 2025 3:48:52 PM

Post#
32270
of 32375
LYEL...6145...Bullish Engulfing Reversal Candle...🥳

LYEL...639...🥳...Looking for $1 plus here...

georgie18

Member Level
Re: None

Thursday, February 13, 2025 4:20:43 PM

Post#
32007
of 32040
LYEL...56...🥳... https://schrts.co/XneECpDw...https://finance.yahoo.com/news/lyell-immunopharma-lyel-upgraded-strong-170012527.html

This is a Rigatoni Play ...one of the best Traders I have had the pleasure of knowing for many years...

👍️0

georgie18 1年前

LYEL...66...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 32041

Wednesday, February 19, 2025 3:48:52 PM

Post#
32270
of 32375
LYEL...6145...Bullish Engulfing Reversal Candle...🥳

LYEL...639...🥳...Looking for $1 plus here...

georgie18

Member Level
Re: None

Thursday, February 13, 2025 4:20:43 PM

Post#
32007
of 32040
LYEL...56...🥳... https://schrts.co/XneECpDw...https://finance.yahoo.com/news/lyell-immunopharma-lyel-upgraded-strong-170012527.html

This is a Rigatoni Play ...one of the best Traders I have had the pleasure of knowing for many years...

👍️0

georgie18 1年前

LYEL...6145...Bullish Engulfing Reversal Candle...🥳

LYEL...639...🥳...Looking for $1 plus here...

georgie18

Member Level
Re: None

Thursday, February 13, 2025 4:20:43 PM

Post#
32007
of 32040
LYEL...56...🥳... https://schrts.co/XneECpDw...https://finance.yahoo.com/news/lyell-immunopharma-lyel-upgraded-strong-170012527.html

This is a Rigatoni Play ...one of the best Traders I have had the pleasure of knowing for many years...

👍️0

georgie18 1年前

LYEL...639...🥳...Looking for $1 plus here...

georgie18

Member Level
Re: None

Thursday, February 13, 2025 4:20:43 PM

Post#
32007
of 32040
LYEL...56...🥳... https://schrts.co/XneECpDw...https://finance.yahoo.com/news/lyell-immunopharma-lyel-upgraded-strong-170012527.html

This is a Rigatoni Play ...one of the best Traders I have had the pleasure of knowing for many years...

👍️0

georgie18 1年前

LYEL...56...🥳... https://schrts.co/XneECpDw...https://finance.yahoo.com/news/lyell-immunopharma-lyel-upgraded-strong-170012527.html

This is a Rigatoni Play ...one of the best Traders I have had the pleasure of knowing for many years...

👍️0

jondoeuk 1年前

There are other bi-specific CARs, including two by GILD's Kite, and at least one tri-specific in development as well.

CRGX's CRG-023 (IND cleared, PhI mid-year) is the first tri-specific CAR-T to express three independent CARs from a single vector, with each CAR having a distinct co-stim domain. One co-stim domain incorporates CD2 signaling, which has been designed to overcome immune-evasion mediated by the loss of CD58 https://ashpublications.org/blood/article/136/Supplement%201/53/470303/CD58-Aberrations-Limit-Durable-Responses-to-CD19

Novel CD19 and CD20 scFvs were selected for enhanced CAR performance and combined with the existing CD22 scFv used in firi-cel. These new binders are fully human to limit host-mediated rejection. The iterative engineering allowed for the selection of the optimal costimulatory domain configuration and optimal assemblage in the lentiviral vector used https://www.sciencedirect.com/science/article/pii/S0006497124047827

👍️0

jondoeuk 1年前

What they don't say is equally as important as what they do say.

Prizlon-cel, is a novel CD19/CD20 bispecific CAR-T. Of the 48 patients infused, 44 had LBCL. No patient experienced a DLT. CRS occurred in 93.8% of patients, with only one case of grade 3. ICANS occurred in 6.3% of patients, with no grade 3 or higher events. The ORR and complete response (CR) rates in all patients were 91.5% and 85.1%, respectively, and in LBCL patients, ORR was 90.7% with 86.0% CR. With median follow up of 30.0 months, median DOR, PFS, and OS were all not reached. The Kaplan-Meier estimate of 2-year DOR, PFS and OS rates were 66.0%, 62.6%, and 76.5%, respectively. https://ashpublications.org/blood/article/doi/10.1182/blood.2024026401/535112/A-phase-1-trial-of-prizloncabtagene-autoleucel-a

The company behind it has signed deals with both AstraZeneca and Janssen. The latter includes this CAR (and another targeting just CD20), which has been granted Regenerative Medicine Advanced Therapy and Fast Track designations by the FDA for the treatment of patients with R/R DLBCL. Now a PhI/II trial is ongoing https://clinicaltrials.gov/study/NCT05800977

👍️0

jondoeuk 1年前

An update https://www.biospace.com/press-releases/lyell-to-highlight-vision-for-its-next-generation-car-t-cell-therapy-pipeline-at-43rd-annual-jp-morgan-healthcare-conference

See slide 10 https://ir.lyell.com/static-files/96379999-4d8e-466b-a5d5-44f5f6f88583

👍️0

glenn1919 1年前

LYEL.................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 2年前

lyel..............................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783

👍️0

glenn1919 2年前

LYEL................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783

👍️0

jondoeuk 2年前

As a reminder, the ORR was ~12.5% for LYL797. BMY's JCAR024 had an ORR of 5-6%, but was discontinued, while a Fred Hutch construct showed no responses.

👍️0

jondoeuk 2年前

An update https://www.globenewswire.com/news-release/2024/10/24/2969054/0/en/Lyell-Immunopharma-to-Acquire-ImmPACT-Bio-and-Prioritizes-its-Pipeline-to-Focus-on-Next-Generation-CAR-T-cell-Therapies.html

The webcast https://lyell-company-update-2024.open-exchange.net/registration

Slides https://ir.lyell.com/static-files/40d6bd34-9ad0-49dd-b816-4bda3bd53eb0

👍️0

glenn1919 2年前

LYEL..........................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783

👍️0

jondoeuk 2年前

Preclinical data (Stim-R tech) https://www.nature.com/articles/s41598-024-72392-1

👍️0

glenn1919 2年前

LYEL..................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783

👍️0

jondoeuk 2年前

(OT) Dr Restifo is Co-founder and Chief Scientist at Marble Therapeutics. From this: ''At Marble Therapeutics, he is working to figure out how to rewind the epigenetic clock on these cells, using any means possible. The company started out with a focus on skin rejuvenation, adds CEO Denitsa Milanova, but expanded to also work on adoptive cell therapy to prove their platform works.'' https://web.archive.org/web/20231218233715/https://www.nature.com/articles/d41573-023-00206-6

They have a license for TIL plus a neoantigen vaccine https://www.federalregister.gov/documents/2024/02/07/2024-02491/prospective-grant-of-an-exclusive-patent-license-vaccine-augmented-adoptive-cell-therapy-for-the

Preclinical data on the vaccine https://jitc.bmj.com/content/11/Suppl_1/A418

🎯 1 👍️ 1

glenn1919 2年前

LYEL.....................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783

👍️0

Monksdream 2年前

LYEL active in the Gaucho session

👍️0

jondoeuk 2年前

Tempting but I will remain on the sidelines.

LYEL..................................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783

👍️0

jondoeuk 3年前

They could be working on this https://ash.confex.com/ash/2023/webprogram/Paper182417.html

👍️0

jondoeuk 3年前

Upcoming https://www.globenewswire.com/news-release/2023/09/27/2750444/0/en/Lyell-Immunopharma-Announces-the-Acceptance-of-Six-Abstracts-for-Presentation-at-2023-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html

LYL119 https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=13739

👍️0

jondoeuk 3年前

Preclinical data from another group (LYL119 will be NR4A3-deficient) https://www.biorxiv.org/content/10.1101/2023.04.21.537841v1.full

👍️0

glenn1919 3年前

LYEL..........................https://stockcharts.com/h-sc/ui?s=LYEL&p=W&b=5&g=0&id=p86431144783

👍️0

jondoeuk 4年前

The FDA has cleared an IND for LYL845. The PhI trial will initially enroll patients with relapsed and/or refractory metastatic or locally advanced melanoma and subsequently expand into NSCLC and CRC. Initial data presentation is expected in 2024.

👍️0

jondoeuk 4年前

SITC titles

NR4A3 gene editing and c-Jun overexpression synergize to limit exhaustion and enhance functional activity of ROR1 CAR T cells in vitro and in vivo

Engineering potent CAR T-cell therapies by controlling T-cell activation signaling parameters using the Stim-R™ technology, a programmable synthetic cell-signaling platform

The Epi-R™ technology produces a polyclonal TIL product (LYL845) with diverse tumor-reactive clones that have stem-like qualities and anti-tumor function

The Epi-R™ technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity

Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-R™ genetic reprogramming technology

👍️0

NY1972 4年前

recent technical advances using culture conditions with IL-7/IL-15 and
the addition of IL-21 may enhance the enrichment for TSCM cells
in the final CART product (74–76), which can be further increased
with the addition of drugs blocking T-cell differentiation, such as
glycogen synthase-3 inhibitors (77). Nevertheless, robust clinical grade protocols for generating TSCM-enriched CART products
have not been developed so far. Recently, a few CART19 clinical
trials for DLBCL have been conducted in which CART products
were manufactured from CD62L+ isolated T cells to generate
cellular products enriched for TCM cells (21, 78); however, due to
prolonged culture conditions, enrichment for TSCM and TCM
subsets in the infused product could not be demonstrated

https://www.frontiersin.org/articles/10.3389/fimmu.2022.904497/full

👍️0

jondoeuk 4年前

The AEs from the LD chemo*. I expect more data (dose expansion is ongoing) from them at ASH. As for NVS, a pivotal trial is planned and DL2 (12.5M) is the recommended dose.

* Some very early clinical data testing an anti-GD2 CAR-T with constitutive signaling from an engineered IL-7 receptor

👍️0

NY1972 4年前

Thanks for the link.
Most commonly reported grade 3/4 AEs were neutrophil count decrease (6/9, 67%), anemia (5/9, 56%), thrombocytopenia (2/9,22%), platelet count decrease (2/9, 22%) and no infection was reported. Complete response rate(CRR) was 78%

Compared to T-Charge
http://www.koreabiomed.com/news/articleView.html?idxno=12767

👍️0

jondoeuk 4年前

For Epi-R, they use media with high concentrations of potassium (as well as multiple cytokines). As for that, T-Charge or BE, I think a product with mostly ''stem-like'' cells and additional edits will be needed. But it doesn't have to be the latter, as shRNA can be used. Here are some clinical data on an anti-CD19 CAR-T with knock-down of both PD-1 and TIGIT https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7522

👍️0

NY1972 4年前

Which will perform better ? BE with 7,8 edits on many genes, Epi secret sauce
or T-Charge which seems to add a CAR only to starting material in order to retain CD4/CD8 ratio.
YTB323 CAR-T cell products generated via this novel expansionless manufacturing process retained the immunophenotype of the input leukapheresis materia

👍️0

jondoeuk 4年前

That depends. Typically, the more the cells expand during manufacturing, the more they differentiate. In the case of ALLO, it seems most are effector memory (manufacturing time is ~19 days and there are a number of steps involved). LYEL refer to this as the expansion/quality paradox. With Epi-R, they have shown they can expand TCR-T cells up to 18 billion by day ten. In addition, these cells are over 94% viable and maintain their ''stem-like'' qualities.

👍️0

NY1972 4年前

Do you need Epigenetic Reprogramming if pts can be treated with healthy, young donor T cells?

👍️0

jondoeuk 4年前

ISSCR poster https://ir.lyell.com/static-files/971404cb-28eb-46fc-839f-b20735899373

👍️0

jondoeuk 4年前

Posters https://ir.lyell.com/static-files/d3a3d05c-1b39-4092-bf82-a486933bc268

https://ir.lyell.com/static-files/6014be8d-4e9d-499b-a496-513d2962f3e4

👍️0

jondoeuk 4年前

1115: Epigenetic Reprogramming (Epi-R™) Yields T-Cell Receptor Products with Improved Stemness, Metabolic Fitness, and Functional Activity in the Presence of Persistent Antigen Exposure https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=2014

661: Preclinical Development of LYL797, a ROR1-Targeted CAR T-Cell Therapy Enhanced with Genetic and Epigenetic Reprogramming for Solid Tumors https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1597

👍️0

jondoeuk 4年前

GSK has updated the master protocol for their next generation constructs to include a third arm with GSK4427296 https://clinicaltrials.gov/ct2/show/NCT04526509

This uses Epi-R.

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Lyell Immunopharma Inc (LYEL)

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

Lyell Immunopharma Inc (LYEL) ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

Form 4 - Statement of changes in beneficial ownership of securities

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

Lyell Immunopharma Announces Participation in May Investor Conferences

LYEL Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Lyell Immunopharma Inc (LYEL)

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

Lyell Immunopharma Inc (LYEL) ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

Form 4 - Statement of changes in beneficial ownership of securities

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

Lyell Immunopharma Announces Participation in May Investor Conferences

LYEL Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する